论文部分内容阅读
目的:分析乳腺癌术后放疗联合复方苦参注射液的临床治疗效果。方法:选取2013年3月至2016年3月我院收治的乳腺癌患者83例,本次治疗前均接受保乳及前哨淋巴结活检术以及5周期的辅助化疗。将患者随机分为对照组42例和观察组41例,对照组患者给予单纯术后放疗治疗,观察组给予患者术后放疗联合复方苦参注射液治疗。比较两组患者治疗前后的血清CA125、CA153及CA724,及CD3~+、CD4~+、CD8~+、CD4~+/CD8~+及NK细胞水平,以及不良反应的发生情况。结果:治疗后,两组的血清CA125、CA153及CA724水平均明显降低,且观察组显著低于对照组,差异具有统计学意义(P<0.05)。观察组的CD3~+、CD4~+、CD8~+、CD4~+/CD8~+及NK细胞数较治疗前明显改善,观察组的CD3~+、CD4~+、CD4~+/CD8~+及NK细胞数显著高于对照组,CD8~+显著低于对照组,差异具有统计学意义(P<0.05)。治疗期间,观察组患者的II度以上皮肤反应、骨髓抑制的发生率均显著低于对照组,差异具有统计学意义(P<0.05)。结论:乳腺癌术后放疗联合复方苦参注射液治疗可显著增强机体的细胞免疫功能,且安全性更高。
Objective: To analyze the clinical effect of postoperative radiotherapy combined with compound Kushen injection for breast cancer. Methods: Eighty-three breast cancer patients admitted to our hospital from March 2013 to March 2016 were selected. Both breast-conserving and sentinel lymph node biopsy and 5-cycle adjuvant chemotherapy were performed prior to this treatment. The patients were randomly divided into control group 42 cases and observation group 41 cases, control group patients were given postoperative radiotherapy alone, the observation group were given postoperative radiotherapy combined with compound Kushen injection. The levels of serum CA125, CA153 and CA724, CD3 +, CD4 +, CD8 +, CD4 + / CD8 + and NK cells before and after treatment in both groups were compared, and the incidence of adverse reactions were also compared. Results: After treatment, the levels of serum CA125, CA153 and CA724 in both groups were significantly decreased, and the observation group was significantly lower than the control group, the difference was statistically significant (P <0.05). The number of CD3 ~ +, CD4 ~ +, CD8 ~ +, CD4 ~ + / CD8 ~ + and NK cells in the observation group were significantly improved compared with those before treatment. The levels of CD3 +, CD4 +, CD4 + / CD8 + And NK cells were significantly higher than the control group, CD8 ~ + was significantly lower than the control group, the difference was statistically significant (P <0.05). During the treatment, the skin reaction grade II and the incidence of myelosuppression in the observation group were significantly lower than those in the control group, the difference was statistically significant (P <0.05). Conclusion: The postoperative radiotherapy combined with Compound Kushen Injection for breast cancer can significantly enhance the cellular immune function and have higher safety.